Real4Reg Final Symposium | 3–4 November 2026 | Lisbon, Portugal

Unlocking Real-World Data with Artificial Intelligence

The Real4Reg Final Symposium took place on 3–4 November 2026 in Lisbon, Portugal (and online) and was hosted by INFARMED, I.P. The symposium presented the main results of the Real4Reg project and discussed the use of real-world data (RWD), artificial intelligence (AI), and machine learning (ML) in regulatory and health technology assessment (HTA) decision-making. The programme included project findings, methodological developments, case studies, and discussions on future implementation and collaboration across Europe.

Real4Reg is a consortium of nine European institutions which aimed to promote the use of real-world data (RWD, e.g. national healthcare registers and claims data) to support decisions about medicines. Real4Reg took advantage of ground-breaking technologies, such as AI and machine ML.

The structure and approach of the project aimed to facilitate the implementation of the effective use of RWD in regulatory and HTA decision-making.

Event details:

  • Title: Real4Reg Final Symposium
  • Date: 3-4 November 2026
  • Location: INFARMED, I.P., Lisbon, Portugal (and online)
  • Address: Parque de Saúde de Lisboa, Avenida do Brasil 53, 1749-004 Lisboa

The findings are informing training activities on good practice examples and will be implemented in existing and emerging guidelines across Europe. Therefore, Real4Reg is contributing to promoting and protecting human health and well-being and supporting the transformation of healthcare systems in their efforts towards equitable access to innovative, sustainable, and effective medicines and health care.

Agenda

Day One: Tuesday 3 November 2026

Click to open

9:00-9:15

Registrations and Welcoming of Participants

9:15-9:45

Opening Session

Dr. Rui Santos Ivo (INFARMED, I.P.’s President) and Cláudia Furtado

9:45-10:25

European Health Data Space (EHDS): Reshaping the Use of Secondary Data

Speaker: Giulia Ancillotti (DG Sante, Digital Health Unit)

Session description

In 2022, the European Commission launched the European Health Data Space (EHDS) initiative, which ultimate purpose is to allow the use and exchange of health data from electronic health record systems in the European Union. In this keynote, the secondary use of health data will be the main focus, with topics such as the value, the barriers, and the impact on multiple stakeholders being discussed.

10:25-10:40

The Future of RWE in Regulatory and HTA Decision-Making: The Contribution of Real4Reg

Speaker: Kerstin Pfeifer (BfArM)

Session description

The availability of medicines requires regulatory and HTA decision-making. Since the current practices might benefit from the inclusion of RWD, the main goal of Real4Reg was to develop, optimise, and implement AI methods for RWD analyses in these contexts. In this introductory session, Real4Reg’s main goals and use cases will be explored, setting the scene for the following sessions.

10:40-11:05

Comfort Break

11:05-12:05

AI and ML: Emerging Opportunities in Regulatory and HTA Decision-Making

Speakers: Mohamed Aborageh and Anna Malewski (Fraunhofer SCAI)
Moderator: Holger Fröhlich (Fraunhofer SCAI)
Roundtable Discussants: Iftekhar Khan (University of Warwick), Mads Nielsen (University of Copenhagen)

Session description

This session focuses on the implementation of AI-supported approaches for the use of RWD in regulatory decision support. It covers methods for the targeted emulation of clinical trials prior to marketing authorisation, for example through the construction of external or synthetic control arms. Following marketing authorisation, methods that enable patient stratification according to estimated treatment effectiveness and the risk of adverse events also become relevant. The session provides a general overview of the implemented methods, which have been incorporated into a reusable Python library.

12:05-13:05

Breast Cancer: Studying Clinical Course and Using Synthetic Data for Underrepresented Subgroups

Speakers: Vera Ehrenstein and Erzsébet Horváth-Puhó (Aarhus University)
Moderator: António Lourenço (Portuguese Cancer Institute of Lisbon)
Roundtable Discussants: Olga Kholmanskikh (FAMHP), Andrea De Censi (Champalimaud Clinical Centre)

Session description

Typical of primary malignancies, breast cancer is well recorded in RWD sources via compulsory cancer registration. Breast cancer is the most common female malignancy, with well-developed treatment protocols. Men with breast cancer are rare and have worse prognosis than women. Among patients with breast cancer, RWD sources may differ in the degree of available disease characteristics, treatment, and prognosis. The session will start by describing clinical course of breast cancer using RWD from Denmark, Finland, and Portugal. Results from data harmonised into the OMOP common data model will be benchmarked against native-format results. Focusing on breast cancer in men, the feasibility and challenges of generating synthetic data for this rare patient subpopulation will be explored.

13:05-14:30

Lunch Break

14:30-15:30

Amyotrophic Lateral Sclerosis: Leveraging RWD and ML in The Preauthorisation Phase

Speakers: Vera Ehrenstein and István Bakos(Aarhus University)
Moderator: Dirk De Valck (EUpALS)
Roundtable Discussants: Christine Leopold (Utrecht University), Miguel Oliveira Santos (Santa Maria Hospital)

Session description

In contrast to primary cancers, there is more variability in recording ALS across RWD sources. ALS is a rapidly fatal disease with limited treatment options. After describing ALS epidemiology and clinical course, Real4Reg attempted to construct an external control arm (ECA) for a hypothetical ALS therapeutic trial. RWD-based ECA to complement preauthorisation evidence in rare disease with limited therapeutic options is a promising area of regulatory interest. Can RWD deliver on this promise?

15:30-15:45

Comfort Break

15:45-16:10

Real4Reg for All: Insights Into Our Training Program

Speaker: Kerstin Pfeifer (BfArM)

Session description

One of Real4Reg’s goals was to develop training activities in data-driven decision-making for a variety of stakeholders, ranging from experts to patients. Therefore, four modules were created, moving from basics of RWD analyses in regulatory decision-making to good practice examples along the product lifecycle and a hands-on analysis. This session will explore each module, helping the audience to understand the type of content and activities available.

16:10-16:35

Appraising Evidence From Target Trial Emulation Studies: Preliminary Findings From a Scoping Review and Survey

Speaker: Christina Tikka and Anni Kokolahti (UEF)

Session description

Target trial emulation (TTE) has emerged as a promising approach for generating causal evidence from real-world data, with growing relevance for regulatory decision-making and health technology assessment (HTA). This presentation reports preliminary findings from a scoping review and online survey among regulators, HTA agencies, methods experts, and systematic reviewers. We examine how evidence from TTE studies is currently assessed, the methodological factors that influence confidence in findings, and the opportunities and challenges associated with assessing TTE evidence at different decision points across the medical product lifecycle. The results provide early insights into stakeholder perspectives and identify key considerations for the future evaluation and uptake of TTE studies in evidence-informed decision-making.

Day Two: Wednesday 4 November 2026

Click to open

9:15-10:45

RWD and Patient Involvement: Contributions to Regulatory and HTA Decision-Making

Beyond Clinical Trials: Learning The Effect of Medicines in The Real World – Speaker: Martin Russek (BfArM)

Patient Involvement in Real World Data Research – Speaker: Diogo Almeida (FFUL)

Moderator: Erica Viegas (INFARMED, I.P.)
Roundtable Discussants: Paulo Gonçalves (RD-Portugal), Kaisa Immonen (EMA)

Session description

Patients and patient benefit are central to all regulatory and HTA decisions. This session is designed specifically for patients, to explore the definition, importance, and impact of different study designs, such as clinical trials and cohort studies. Afterwards, patient involvement in RWD research will be discussed, namely its’ value, the barriers encountered, and the measures that need to be taken to strengthen this practice.

10:45-11:25

Making it Count: How Data Analysis and Real World Interrogation Network (DARWIN EU) is Contributing to Medicines’ Safety and Effectiveness

Speaker: Annika Jödicke (University of Oxford)

Session description

DARWIN EU is a European network which aims to support decision-making in medicines lifecycle through RWD available in multiple databases located in different countries. In this session, the project will be presented, exploring topics such as main goals, impact in different stakeholders, challenges, and future steps.

11:25-11:55

Comfort Break

11:55-12:55

Evaluating the Impact of Regulatory Actions and Risk of Adverse Outcomes With ML Assisted Methods: Focus on Fluoroquinolones

Speaker: Saara Puustinen (UEF)
Moderator: Márcia Silva (INFARMED, I.P.)
Roundtable Discussants: Carla Torre (FFUL), Martin Huber (BfArM)

Session description

The Use Case 3 in the Real4Reg project focused on fluoroquinolone antibiotics. The first sub-study investigated their use and user characteristics and whether there were changes over time in relation to regulatory safety interventions. In the second sub-study, the risk of several adverse drug reactions was investigated: aortic aneurysm and dissection, cardiac arrhythmia and sudden cardiac death, drug-induced liver injury and polyneuropathy. Machine learning and artificial intelligence had a key role in this target trial emulation study. In this session, the results of both sub-studies will be presented.

12:55-14:00

Lunch Break

14:00-15:00

Targeting the Drug Benefits in Real-World Settings: Lessons Learnt From Target Trial Emulation for SGLT2 Inhibitors

Speakers: Thuan Vo and Eeva Pylkkö (UEF)
Moderator: Anna-Maija Tolppanen (UEF)
Roundtable Discussants: Reimar Thomsen (Aarhus University), Andrei Barbulescu (EMA)

Session description

The presentation will focus on the utilisation of SGLT2 and DPP-4 inhibitors, and the effectiveness of SGLT2 inhibitors in routine care. The national trends in the uptake of these medications will be presented and how the emergence of evidence of the additional health benefits of SGLT2 inhibitors has been reflected in real-world prescribing patterns will be explored. It will also report findings from a nationwide comparative effectiveness study comparing initiators of SGLT2 inhibitors with initiators of DPP-4 inhibitors, using heart failure as the primary outcome, and evaluate how alternative cohort entry definitions affect treatment effect estimates. The design of an ongoing target trial emulation study aimed at comparing the effectiveness of SGLT2 inhibitors and DPP-4 inhibitors using machine learning methods will be introduced

15:00-15:15

Wrapping Up Real4Reg: The Lessons Learnt and The Way Forward

Speaker: Cláudia Furtado (INFARMED, I.P.)

Session description

After four years of hard work, Real4Reg is now coming to an end. Therefore, now is the time to look back at all the achievements, lessons learnt, and impacts that the project had in multiple stakeholders. Has Real4Reg changed the way RWD is perceived and used in regulatory and HTA decision-making?

Speakers, Moderators, and Panellists

Andrea De Censi

Director, Breast Department

Read more

Andrea De Censi graduated in Medicine and Surgery with first class honours at the Medical School University of Pavia in 1984. He went on to specialise in Medical Oncology at the Postgraduate Medical School, University of Genoa, Italy in 1987. In 2008 he earned the ESMO European Certification in Medical Oncology.

Dr De Censi became tenured assistant at the National Institute for Cancer Research in Genoa and since 1998 he worked as Medical Oncologist and Clinical Researcher at the same Institute.

Between 1995 and 2003 he was Medical Director of the Cancer Prevention and Genetics Division of the European Institute of Oncology in Milan, Italy.

From 2004 to 2025 Dr De Censi was Director of the Medical Oncology Unit and the Department of Medicine and Geriatrics of the Galliera Hospital in Genoa.

In November 2025, he was appointed as Director of the Breast Unit at the Champalimaud Clinical Centre in Lisbon, Portugal.

In 2013, he received the National Scientific Qualification as University Full of Medical Oncology, and has been Honorary Professor at the Queen Mary University of London, UK.

Dr De Censi dedicated his career to cancer prevention and minimally toxic therapeutic strategies, with a lifelong focus on breast cancer. He has been principal investigator in more than 50 clinical trials and holder of a Master agreement with the US National Cancer Institute for phase I and II clinical trial in cancer prevention. He is the author of over 300 peer reviewed publications with a H-index of 59 and reviewer for the most important oncology journals.

Portrait

Andrei Barbulescu

Pharmacoepidemiologist, EMA

Read more

Anna Malewski

PostDoc Biomedical AI & Data Science

Read more

Trained as an applied mathematician, Anna Malewski joined Fraunhofer SCAI in 2025 with the intention of contributing to relevant applications of AI and data science in biomedicine. The objective of her current research is to apply causal machine learning methods to support regulatory decision-making based on real-world data.

Anna-Maija Tolppanen

Professor of Pharmacoepidemiology & Real-World Data Analytics

Read more

Anna-Maija Tolppanen is a professor of pharmacoepidemiology and real-world data analytics. The overarching aim of her research is to develop and implement methods and approaches for evaluating the effectiveness and safety of treatments by using real-world data. The applied data ranges from national register-based studies to multi- and single-center studies using data from electronic medical records and medical reports as well as data collected specifically for research purposes.

Her group has produced internationally recognised real-world evidence on utilisation and outcomes of different treatments, compared and validated different patient-reported outcome measurements and determined clinically important threshold values for them, and evaluated health inequalities in neurodegenerative disorders.

Anni Kokolahti

Project Researcher

Read more

Anni is a Project Researcher at the School of Pharmacy, University of Eastern Finland. She has an MSc in Pharmacy. Her work in the Real4Reg project focuses on how evidence from target trial emulation studies is assessed and the opportunities and challenges involved in evaluating this evidence at different decision points across the medical product lifecycle.

Annika Jödicke

Senior Researcher in Pharmacoepidemiology

Read more

Annika Jödicke’s work as a pharmacoepidemiologist is to improve healthcare for patients by using de-identified healthcare data to generate robust and reliable real-world evidence on the utilisation, safety and effectiveness of medicines. She is a pharmacist by training, and joined the Health Data Sciences Group in 2020 after completing her doctoral training at ETH Zurich, Switzerland. Several of her projects use data from across Europe, mapped to the OMOP common data model. Annika has a particular research interest and expertise in geriatric pharmacoepidemiology, vaccine effectiveness research and regulatory pharmacoepidemiology. Her areas of work include conducting causal inference and drug utilisation studies for the national and European regulators (e.g. in the context of DARWIN EU) as well as methodological work to minimize confounding bias in observational studies. Since May 2025, she is honoured to co-lead with Prof. Prieto-Alhambra the academic side of the Innovative Health Initiative’s GREG project to generate, pilot-test, and disseminate evidence-based guidance for the use of real-world evidence to support regulatory and HTA decision-making.

António Lourenço

Head of the Epidemiology Research Unit and Cancer Registry

Read more

António Lourenço is a medical doctor graduated from the Faculty of Medicine of the University of Lisbon, senior consultant, clinical pharmacologist, and holds postgraduate qualifications in Public Health and Epidemiology from NOVA National School of Public Health, as well as in Bioethics from Faculty of Medicine of the University of Lisbon. He currently works at the Portuguese Oncology Institute of Lisbon Francisco Gentil (IPOLFG), where is the Head of the Epidemiology Research Unit and Cancer Registry, Coordinator of the South Portugal Cancer Registry (ROR-Sul), and member of the Pharmacy and Therapeutics Committee. He is also a member of the Health Technology Assessment Commission (CATS, INFARMED) and an Invited Assistant Professor of Medical Therapeutics at NOVA Medical School. One of the main interest and research area is therapeutic effectiveness. Former Vice-President of the National Ethics Committee for Clinical Research (CEIC).

Carla Torre

Assistant Professor at University of Lisbon

Read more

Carla Torre is an assistant Professor with Habilitation of Pharmacoepidemiology, Pharmacovigilance/Risk Management and Public Health at the Faculty of Pharmacy of the University of Lisbon (FFUL), Portugal and the coordinator of the Master in Regulation and Evaluation of Medicines and Health Products at FFUL.

Carla graduated in Pharmaceutical Sciences (University of Lisbon), holds a post-graduate Diploma in Pharmacy and Medicinal Products Law (University of Coimbra), a master’s degree in Epidemiology (University of Porto) and a PhD in Pharmacoepidemiology (University of Lisbon). In 2020, Carla Torre concluded the Postgraduate Professional Development course in Pharmacoepidemiology and Pharmacovigilance at the London School of Hygiene & Tropical Medicine. Over the years she completed several specialization and training courses in design, conducting, analysis and interpretation of pharmacoepidemiology/ pharmacovigilance, clinical trials and statistics research (e.g. McGill University, Utrecht University, Groningen University, Harvard T.H. Chan).

Carla Torre leads the Epidemiology, Pharmacoepidemiology & Pharmacovigilance sub-group of the Laboratory of Systems Integration Pharmacology, Clinical & Regulatory Science at the Research Institute for Medicines (imed.UL) hosted at the University of Lisbon. She has more than 20 years of solid and hands-on experience in Pharmacoepidemiology arena, including all steps of conducting real-world drug research studies and interpretating data in different environments and across various therapeutic areas. Carla Torre is the co-opted member for Pharmacoepidemiology of the Committee for Medicinal Products for Human Use (CHMP), alternate member of the Pharmacovigilance Risk Assessment Committee (PRAC) and Member the Methodology Working Party at the European Medicines Agency. She is member of the Evaluation Board of Medicines of the Portuguese National Authority of Medicines and Health Products – INFARMED. Carla Torre serves as an Expert in Pharmacoepidemiology for the Pharmacovigilance Unit of Lisboa, Setúbal e Santarém. For two mandates (2016-2021), Carla Torre was as the Secretary General of the Portuguese Pharmaceutical Society. Previously, she was head of the Pharmacoepidemiology division at the Center for Health Evaluation & Research of the National Association of Pharmacies (2009-2016) where she held responsibilities on conducting pharmacoepidemiology and outcomes research studies. Between 2006 and 2009 she was technical advisor to the National Coordinator for HIV/AIDS Infection of the Ministry of Health.

Christina Tikka

Project Researcher

Read more

Christina Tikka is a project researcher at the University of Eastern Finland. She holds a PhD in Evidence-Informed Decision Making from the University of Amsterdam and has a background in public health and occupational health and safety. Her research focuses on evidence synthesis, evidence-informed decision-making, health services research, and the evaluation of real-world evidence for healthcare, health technology assessment, and regulatory decision-making. Before joining the University of Eastern Finland, she worked as a systematic reviewer and research consultant, conducting systematic reviews and mixed-methods studies for organizations including Cochrane, EU agencies, Council for Choices in Health Care in Finland (PALKO), and the Finnish Institute of Occupational Health. Her research has contributed to healthcare policy, guideline development, and healthcare decision-making in Finland and internationally.

Christine Leopold

Christine Leopold

Assistant Professor of Drug Regulatory Science

Read more

Dr. Leopold is an Assistant Professor of Drug Regulatory Science at the Division of Pharmacoepidemiology & Clinical Pharmacology at the Utrecht Institute for Pharmaceutical Science / WHO Collaborating Centre for Pharmaceutical Policy and Regulation. Her research focuses on evaluating pharmaceutical policies along the drug life cycle with the aim to improve affordable access to medicines. She has a particular interest in understanding European regulatory, HTA and pricing/funding processes within cancer care and for orphan medicinal products and uses various data sources (such as from registries, claims data from insurers, legal and policy documents as well as interview data) in her research.
From 2014 to 2018, Dr. Leopold was a Senior Research Fellow in the Department of Population Medicine at Harvard Medical School and the Harvard Pilgrim Health Care Institute. Prior to that, she worked as a senior researcher at the Austrian Public Health Institute, Department of Health Economics / WHO Collaborating Center for Pharmaceutical Pricing and Reimbursement Policies, where she co-led the Austrian Centre for Rare Diseases as well as the European Network of public authorities of Pharmaceutical Pricing and Reimbursement Information (PPRI).
She holds a doctorate in Pharmaceutical Policy from Utrecht University, Utrecht Institute for Pharmaceutical Science / WHO Collaborating Centre for Pharmaceutical Policy and Regulation, a Master of International Health Care Management, Economics and Politics from Bocconi University (Italy) and a Master of International Business Relations from the University of Applied Science (Austria).

Cláudia Furtado

INFARMED I.P.’s Head of Information and Strategic Planning Division

Read more

Cláudia Furtado is Director of Infarmed’s Information and Strategic Planning Department at INFARMED – Autoridade Nacional do Medicamento e Produtos de Saúde, I.P. She is INFARMED’s representative on several European networks, namely National Competent Authorities for Pricing and Reimbursement, WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies and the International Horizon Scanning Initiative. She is on the advisory board of the DARWIN EU project and the Steering Board of the RWE4Decisions consortium. Cláudia Furtado is a Visiting Assistant Professor at the NOVA NSPH. Her experience and research focus on the area of medicines, aspects related to medicines policy, health technology assessment and the financing of medicines, and the monitoring of their use and effectiveness. She also works on the analysis of equity in healthcare provision and financing, with a particular focus on the area of medicines.

Dirk De Valck

Dirk De Valck

Staff EUpALS

Read more

Dirk De Valck is a PhD in Molecular Biology. After having completed an academic career at different universities in Belgium, he decided to devote himself to patient advocacy with focus on addressing the unmet needs of people with ALS. Therefore, he joined the international non-profit organization EUpALS – The European Organization for Professionals and People with ALS. His responsibilities include close interaction with the EUpALS Patients and Carers Expert Board, providing advice in ALS clinical research from a patient perspective.

Diogo Almeida

PhD Candidate

Read more

Diogo Almeida holds an MSc in Pharmaceutical Sciences from the Faculty of Pharmacy, University of Lisbon and is currently pursuing a PhD in Pharmaceutical Sciences at the same institution, specialising in pharmacoepidemiology. His research interests include the use of real-world data and patient experience data in regulatory and health technology assessment decision-making, work that he is developing through the EU-funded More-EUROPA consortium and in collaboration with the European Medicines Agency.

Eeva Pylkkö

Doctoral Researcher

Read more

Eeva is a Doctoral Researcher at the School of Pharmacy, University of Eastern Finland. She has an interdisciplinary background in mathematics (MSc) and pharmacy (BPharm). Before starting her doctoral studies, she worked as a subject teacher and a pharmacist. Her doctoral research focuses on the identification of risk factors for neurodegenerative diseases using machine learning methods.

Erica Viegas

Erica Viegas

Advisor to the Infarmed Executive Board

Read more

Erica Viegas graduated in Pharmaceutical Sciences from the Faculty of Pharmacy of the University of Lisbon and holds a specialization in Hospital Administration.

She is currently Advisor to the Executive Board of INFARMED. From July 2022 to December 2025, she served as a Member of INFARMED’s Executive Board.

She is an Invited Assistant Professor at the Faculty of Pharmacy of the University of Lisbon. Erica began her professional career in 2003 at Hospital de São Francisco Xavier, where she served as Coordinator of the Pharmaceutical Services from 2012 to 2022. During her hospital career, she was actively involved in several multidisciplinary committees and working groups, particularly in the areas of medicines policy, quality, patient safety and antimicrobial stewardship.

Erzsébet Horváth-Puhó

Associate Professor at the Department of Clinical Epidemiology and Data Science and Center for Population Medicine, Aarhus University

Read more

Associate Professor Erzsébet Horváth-Puhó is a leading researcher with more than 310 peer-reviewed publications and a Scopus h-index of 53. Dr. Horváth-Puhó is dedicated to advancing epidemiological research through the development and application of novel methodologies, including biostatistical and AI/machine learning techniques, as well as the establishment of comprehensive nationwide cohorts based on Danish registries. For more than a decade, she led a group of biostatisticians at the Department of Clinical Epidemiology and conducted research in women’s and child health epidemiology, venous thromboembolism, cancer epidemiology, and clinical trials.

Her work has significantly advanced the understanding of newborn and infant vulnerability, particularly the short- and long-term impacts of early-life exposures on children and their families. Dr. Horváth-Puhó plays a key role in international research on Group B Streptococcus (GBS) infection in infants, including organizing the Readiness for Group B Streptococcus Maternal Immunisation Symposium in 2026 and serving as Chair of the GBS Vax Ready European Consortium. Her research findings on GBS have contributed to global disease burden estimates and have informed vaccination strategies developed by the WHO.

Giulia Ancillotti

Policy Officer, DG Sante (Digital Health Unit)

Read more

Giulia Ancillotti is a Policy Officer at the European Commission (DG SANTE, Digital Health unit) working on the implementation of the European Health Data Space (EHDS) Regulation, with focus on secondary uses of data. Previously, she worked at DG CNECT (Artificial intelligence in health and life sciences unit) on Digital Health programmes and policies.

Giulia holds a Master of Arts degree in European Political and Governance Studies from the College of Europe and a Master of Science in Global Health Policy from the London School of Economics (LSE).

Holger Fröhlich

Holger Fröhlich

Head of the Department of Biomedical AI & Data Science, Fraunhofer SCAI; Professor for Biomedical Data Science, Institute for Digital Medicine & b-it University of Bonn, University Hospital Bonn

Read more

Prof. Dr. Holger Fröhlich holds a Diploma (with a specialization in Artificial Intelligence) and a PhD in Computer Science. After postdoctoral research at the German Cancer Research Center and a subsequent position as Senior Scientist at Cellzome AG (now part of GlaxoSmithKline), he was appointed Associate Professor at the University of Bonn in 2010.

In 2015, he joined the global biopharmaceutical company UCB, where he became Director of an AI and Data Science research team. From December 2019 to December 2025, he served as Head of the AI & Data Science Group and Deputy Head of the Department of Bioinformatics at the Fraunhofer Institute for Algorithms and Scientific Computing (SCAI) in Sankt Augustin. Since January 2026, he has been Head of the Department of Biomedical AI & Data Science at the same institute.

In parallel, he teaches as a Full Professor in the Master programs Life Science Informatics and Computer Science at the University of Bonn. Since October 2025, he has also been affiliated with the Institute for Digital Medicine at the University Hospital Bonn.

Holger Fröhlich’s focus is on the development and application of data science (specifically AI/ML) methods in biomedicine, with focus on target prioritization, precision medicine and clinical trials. In this context, Holger Fröhlich has developed over the last 20 years a broad spectrum of data science approaches, including techniques for multi-modal data integration, (generative) time series modeling, hybrid AI approaches (ODE/NN combinations, Graph Neural Networks) and causal machine learning. He is author and co-author of more than 190 scientific publications. He has been coordinator of three EU projects (JNPD ADIS, ERA PerMed DIGIPD, Marie-Sklodowska-Curie doctoral network AIPD), and partner in multiple further national and international research consortia as well as industry collaborations. Furthermore, he is scientific advisory board member of the international AI graduate school HIDSS4Health of the Helmholtz society.

Iftekhar Khan

Iftekhar Khan

Biostatistician and Health Economist

Read more

Dr Iftekhar Khan is a biostatistician and health economist with over 20 years of experience spanning the pharmaceutical industry, regulatory agencies and academia. He has held high ranking academic appointments in statistics and health economics at the Universities of Oxford, Warwick and Exeter, King’s College London and University College London (CRUK & UCL Cancer Trials Centre). He has authored over 100 peer-reviewed publications and two books in biostatistics and health technology assessment (HTA). Prof Khan has also previously served as an Expert Statistical Assessor at the European Medicines Agency (EMA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).

His expertise spans clinical trial design, Bayesian and adaptive methodologies, statistical modelling and simulation, real-world evidence, artificial intelligence and machine learning, synthetic data generation, and advanced HTA methodologies. He helped developed key technologies in synthetic data generation using AI technology during his time at Warwick University. Dr Khan currently advises as a Scientific Lead at Novartis, providing scientific and methodological leadership at the intersection of real-world evidence, HTA and interventional clinical trials and is also a visiting Professor of Medical Statistics at the Aga Khan University.

© Lars Kruse, AU Foto

István Bakos

Biostatistician at the Department of Clinical Epidemiology, Aarhus University

Read more

Trained as an applied mathematician, István joined the Department of Clinical Epidemiology at Aarhus University in September 2019. Since then, he has contributed to a broad range of epidemiological research projects, with a primary focus on large-scale data management, statistical analysis, and data visualisation.

Kaisa Immonen

Patient Engagement Liaison, EMA

Read more

Kaisa Immonen joined the Stakeholders and Public engagement team of the European Medicines Agency (EMA) in 2023. She supports interactions with patients, consumers and their organisations, in particular patients’ involvement in scientific advice and the initiative on patient experience data. Kaisa holds a Master’s degree in Health Policy, Management and Innovation (Maastricht University) and a Master’s in International Relations (University of Kent at Canterbury/Tampere University). She has extensive experience of EU health policy and patient advocacy and as Director of Policy at the European Patients’ Forum and co-chaired the EMA Patients and Consumers Working Party in 2016-2022. She contributed among other things to the OECD’s work on quality and safety of healthcare and the PaRIS surveys, WHO Europe’s work on people-centred health systems, and to European projects related to patient safety, patient empowerment, health literacy and vaccines communication.

Kerstin Pfeifer

Kerstin Pfeifer

Real4Reg Project Coordinator

Read more

Kerstin Pfeifer is a Project Coordinator at BfArM with over five years of experience at the intersection of health policy, global health, and healthcare innovation. Prior to joining BfArM, she worked with GIZ and IOM in the field of international public health, supporting initiatives to strengthen vaccine access and manufacturing capacities globally. Holding a Master’s degree in Medical Science and Public Health from Lund University, she brings a broad international perspective to healthcare challenges. In her current role at BfArM, she coordinates the Real4Reg project, fosters successful collaboration among all project partners, and supports the development of Real4Reg’s training programme.

Mads Nielsen

Professor

Read more

Mads Nielsen has and M.Sc. in Computer Science and Ph.D. in Image Analysis from University of Copenhagen. He has done research in the mathematical foundation of image analysis, computer vision, medical image analysis, and the foundation of quantitative imaging biomarkers and their use in epidemiology. He has published more than 300 research papers, graduated more than 45 Ph.D.s and is currently principal investigator on research grants for 100 MDKK+. Currently he is professor at Department of Computer Science, University of Copenhagen, Pioneer Centre for AI, and CEO and co-founder of Biomediq A/S, and co-founder of Aiomic, Cerebriu, Prenaital.

Márcia Silva

INFARMED, I.P.’s Head of Pharmacovigilance

Read more

Márcia Silva has been Director of the Directorate for Medicines Risk Management (DGRM) at INFARMED since 2021. She graduated in Pharmaceutical Sciences from the Faculty of Pharmacy of the University of Coimbra in 1999. She worked in community pharmacy from 1999 and obtained the Specialist Qualification in Community Pharmacy in 2009. In 2014, she joined INFARMED, I.P. as a pharmacovigilance officer. Between 2016 and 2022, she was appointed as Portugal’s alternate representative on the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA).

Martin Huber

Head of Pharmacovigilance Division

Read more

Dr Martin Huber is the head of BfArM’s division of pharmacovigilance. Being a pharmacist by training and holding a master’s degree in public health he joined BfArM in 2010. From 2012 to 2026 he was the German member of the Pharmacovigilance Risk Assessment Committee (PRAC) and also served as its vice-chair for 6 years. He has been actively involved in many pharmacovigilance procedures at PRAC and also contributed to the work of several working groups at the European level.

Martin Russek

Martin Russek

Doctoral Researcher

Read more

Martin is a statistician by training and has been working at BfArM since 2023 as a doctoral researcher and scientist in the Real4Reg project. Prior to joining BfArM he spent a year as a trainee at the European Medicines Agency. His research interests lie in time-varying confounding and causal inference methods for observational studies.

Mohamed Aborageh

Mohamed Aborageh

Research Associate/PhD Candidate

Read more

Mohamed is a researcher and PhD candidate at Fraunhofer SCAI. His work focuses on biomedical data science and artificial intelligence, particularly in the context of complex and neurodegenerative diseases. He has worked with large-scale datasets such as UK Biobank and PPMI and is currently involved in the EU-funded Real4Reg project. Mohamed has a background in pharmacy and a master’s degree in Life Science Informatics from B-IT in Bonn.

Olga Kholmanskikh

Olga Kholmanskikh

Clinical Assessor

Read more

Olga Kholmanskikh is a clinical assessor at the Belgian National Competent Authority, Federal Agency for Medicines and Health Products (FAMHP), since 2012. She is an MD by training and holds PhD in Biomedical and Pharmaceutical Sciences. She is a member of the EMA’s Oncology, Methodology and Scientific Advice Working Parties as well as an alternate member at the Committee for Advanced Therapies (CAT).

© 2022 Carlos Mendes Fotografia

Paulo Gonçalves

Co-Founder and Executive President of Portuguese Union of Rare Disease Associations (RD-Portugal)

Read more

Paulo is 58 years old and has two extraordinary kids. He studied Applied Mathematics and Computational Sciences and worked in technology and business transformation consulting for about 30 years. Paulo was diagnosed with secondary progressive multiple sclerosis when he was forty and with two kids to raise, he started working on his recovery with one-hour sessions, three times a week, for more than 150 weeks. He walked again and the self-confidence allowed him to say in 2018 when he completed 50 years that “if his forties were his best decade so far, the fifties would be even better”. He just never imagined that it would be in patients with rare or chronic diseases advocacy.

He was the vice-president of the board of the Portuguese Society of Multiple Sclerosis for seven years. Paulo is now President of the General Assembly of SERaro.pt, President of the Fiscal Council of “Health in Dialogue Platform” and President of RD-Portugal (Union of Rare Disease Associations) since its foundation in May 2021, where around 50 rare diseases associations are gathered. He is a member of the experts group of the “More Data Better Health Program”, represents rare diseases in Portugal in the EURORDIS’ Council of National Alliances, is a member of the National Mirror Group to new European platform ERDERA (following EJPRD), represents people with rare diseases on PT_Med_Gen (the working group for the Portuguese National Strategy for Genomic Medicine), and represents RD-Portugal in the “Action Plan for Rare Diseases: From Strategy to Person 2025-2030”. Paulo is part of the Portuguese Order of Physicians Commission for Artificial Intelligence and he was nominated the Portuguese Order of Pharmacists Ombudsman for Service Recipients, in June 2024. He has a special interest in personal data security and in the safe utilisation of data to scientific progress, for the benefit of patients, but without neglecting health systems sustainability. 

Favourite book: “Start with why” by Simon Sinek

Favourite song: “Nothing’s gonna stop us now” by Starship”

Favourite value: Empathy

Reimar Thomsen

Reimar Thomsen

Professor and Consultant Physician (Clinical Epidemiology) at the Department of Clinical Epidemiology, Aarhus University

Read more

Reimar is a consultant physician and professor of metabolic disease epidemiology at the Department of Clinical Epidemiology, Aarhus University & Aarhus University Hospital. He received his medical degree at Aarhus University in 1998 and defended his PhD in clinical epidemiology here in 2004. Currently he coordinates the metabolic disease epidemiology research program at their department at Aarhus University. He has ample experience with research project management and public-private collaboration projects with partners in the pharmaceutical industry. Reimar is a board member of the Danish Epidemiological Society, and advisor for the Danish Ministry of Health and the Danish Medicines Agency. His research activities are primarily focused on research based on clinical databases and registries and the primary fields of interest are pharmacoepidemiology and metabolic disease epidemiology, including complications of type 2 diabetes and obesity. Reimar has published about 375 papers in peer-reviewed scientific journals.

Saara Puustinen

Saara Puustinen

Project Researcher

Read more

Saara is a Project Researcher at the School of Pharmacy, University of Eastern Finland. In the Real4Reg project, her responsibilities focus on UC3, the fluoroquinolone study, including the preparation of scientific manuscripts and training material. Her background is in clinical pharmacy, and prior to joining the Real4Reg team, she worked as a hospital pharmacist for two years.

Thuan Vo

Project Researcher at School of Pharmacy, UEF

Read more

Dr. Thuan Vo is a medical epidemiologist and researcher at the University of Eastern Finland. His research focuses on pharmacoepidemiology and the use of real-world data to evaluate the safety and effectiveness of medicines.

Vera Ehrenstein

Professor at the Department of Clinical Epidemiology, Aarhus University

Read more

Vera Ehrenstein is the scientific lead of Work Package 1 in Real4Reg. She is professor for phase IV studies at the Department of Clinical Epidemiology and Data Science, at Aarhus University, Denmark. She coordinates large multi-database studies on safety of medicines and vaccines, including regulator-mandated and industry-commissioned studies. Professor Ehrenstein has served on the Board of Directors of the International Society for Pharmacoepidemiology (ISPE) and is currently a member of the Steering Group of the European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCePP). In that capacity, she is continuously contributing to development of methodological guidelines, most recently, as the coordinating author of the guideline for conducting safety studies in pregnancy and breastfeeding using real-world data. She is the lead author of the ISPE-sponsored and endorsed guideline on validation of RWD-based algorithms and contributes to the RECORD-PE reporting guidelines.

Objectives: To enable the use of RWD/RWE; To establish the value of RWD/RWE; To impact RWD/RWE use and analyses; Real4Reg: Real-World Evidence (RWE) from Real-World Data (RWD)in regulatory decision-making and Health Technology Assessment (HTA); Solutions: Analytical Solutions, Usable Standards, Guidance and Training
© Real4Reg